

Appendix 4

Annual costs, effects and cost-effectiveness of interventions in cervical cancer control (cost and effects discounted and effects age-weighted)

| Intervention | Costs per capita (I\$) | DALYS averted (per mln people) | Cost per DALY | |
|---|------------------------|--------------------------------|---------------|-----------|
| | | | ACER | ICER |
| World sub-region Afr-E | | | | |
| Current Scenario | 0.06 | 24 | 2,703 | Dominated |
| 50% coverage | | | | |
| Pap (1,20,65)* | 0.66 | 198 | 3,340 | Dominated |
| Pap (3,20,65)* | 0.48 | 170 | 2,808 | Dominated |
| VIA (40)* | 0.05 | 88 | 555 | Dominated |
| Rx | 0.08 | 188 | 405 | Dominated |
| Pap (1,20,65)* + Rx | 0.73 | 403 | 1,821 | Dominated |
| Pap (3,20,65)* + Rx | 0.56 | 378 | 1,470 | Dominated |
| VIA (40)* + Rx | 0.16 | 487 | 335 | Dominated |
| Pap (5,20,65)* | 0.32 | 156 | 2,074 | Dominated |
| Pap (5,20,65)* + Rx | 0.40 | 364 | 1,110 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) | 1.38 | 208 | 6,652 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) + Rx | 1.39 | 413 | 3,370 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) | 0.74 | 185 | 4,028 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) + Rx | 0.80 | 391 | 2,040 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) | 0.49 | 175 | 2,779 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) + Rx | 0.56 | 382 | 1,470 | Dominated |
| Pap (35,40,45)*. | 0.07 | 126 | 575 | Dominated |
| Pap (35,40,45)* + Rx. | 0.19 | 528 | 362 | Dominated |
| HPV (35,40,45)*. | 0.20 | 139 | 1,427 | Dominated |
| HPV (35,40,45)* + Rx | 0.30 | 502 | 607 | Dominated |
| VIA (35,40,45) | 0.11 | 136 | 792 | Dominated |
| VIA (35,40,45)* + Rx | 0.21 | 499 | 428 | Dominated |
| Pap (40)* | 0.03 | 78 | 414 | Dominated |
| Pap (40)* + Rx | 0.15 | 478 | 307 | 307 |
| HPV (40)* | 0.08 | 93 | 875 | Dominated |
| HPV (40)* + Rx | 0.19 | 491 | 391 | Dominated |
| HPVAC(12), \$0.60/vaccine dose | 0.05 | 129 | 355 | Dominated |
| HPVAC (12), \$0.60/vaccine dose + Rx | 0.15 | 308 | 489 | Dominated |
| HPVAC (12), \$2.00/vaccine dose | 0.09 | 129 | 693 | Dominated |
| HPVAC (12), \$2.00/vaccine dose + Rx | 0.20 | 308 | 642 | Dominated |
| Pap(1,20,65)*+HPVAC (12,\$.60) | 0.64 | 259 | 2,464 | Dominated |
| Pap(3,20,65)*+HPVAC (12,\$.60) | 0.49 | 244 | 2,028 | Dominated |
| VIA(40)*+HPVAC (12), \$.60) | 0.08 | 165 | 507 | Dominated |
| Pap(1,20,65)*+HPVAC (12, \$.60) + Rx | 0.71 | 429 | 1,657 | Dominated |
| Pap(3,20,65)*+HPVAC (12, \$.60) + Rx | 0.57 | 415 | 1,368 | Dominated |
| VIA(40)*+HPVAC (12, \$.60) + Rx | 0.18 | 341 | 526 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) | 0.35 | 233 | 1,488 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) + Rx | 0.43 | 405 | 1,054 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60) | 1.36 | 266 | 5,105 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60)+Rx | 1.43 | 436 | 3,275 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60) | 0.78 | 254 | 3,080 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60)+Rx | 0.85 | 425 | 2,010 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60) | 0.53 | 247 | 2,123 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60)+Rx | 0.60 | 418 | 1,432 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60) | 0.11 | 188 | 588 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.21 | 362 | 583 | Dominated |

| | | | | |
|---|------|-----|-------|-----------|
| HPV (35,40,45)* +HPVAC (12,\$.60) | 0.24 | 195 | 1,218 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.33 | 368 | 886 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60) | 0.24 | 193 | 1,251 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.24 | 366 | 649 | Dominated |
| Pap (40)* +HPVAC (12,\$.60) | 0.07 | 161 | 441 | Dominated |
| Pap (40)* +HPVAC (12,\$.60)+Rx | 0.17 | 337 | 494 | Dominated |
| HPV (40)* +HPVAC (12,\$.60) | 0.12 | 167 | 700 | Dominated |
| HPV (40)* +HPVAC (12,\$.60)+Rx | 0.21 | 343 | 620 | Dominated |
| 80% coverage | | | | |
| Pap (1,20,65)* | 1.05 | 317 | 3,313 | Dominated |
| Pap (3,20,65)* | 0.61 | 273 | 2,237 | Dominated |
| VIA (40)* | 0.06 | 141 | 398 | Dominated |
| Rx | 0.17 | 426 | 403 | Dominated |
| Pap (1,20,65)* + Rx | 1.21 | 708 | 1,703 | Dominated |
| Pap (3,20,65)* + Rx | 0.78 | 672 | 1,154 | Dominated |
| VIA (40)* + Rx | 0.28 | 662 | 428 | Dominated |
| Pap (5,20,65)* | 0.40 | 249 | 1,618 | Dominated |
| Pap (5,20,65)* + Rx | 0.58 | 652 | 887 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) | 2.20 | 332 | 6,622 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) + Rx | 2.25 | 724 | 3,103 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) | 1.00 | 296 | 3,397 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) + Rx | 1.10 | 693 | 1,592 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) | 0.64 | 280 | 2,298 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) + Rx | 0.81 | 679 | 1,187 | Dominated |
| Pap (35,40,45)*. | 0.10 | 201 | 491 | Dominated |
| Pap (35,40,45)* + Rx. | 0.33 | 713 | 469 | Dominated |
| HPV (35,40,45)*. | 0.28 | 223 | 1,268 | Dominated |
| HPV (35,40,45)* + Rx | 0.49 | 711 | 695 | Dominated |
| VIA (35,40,45) | 0.12 | 217 | 569 | Dominated |
| VIA (35,40,45)* + Rx | 0.34 | 706 | 475 | Dominated |
| Pap (40)* | 0.04 | 125 | 339 | Dominated |
| Pap (40)* + Rx | 0.27 | 649 | 418 | Dominated |
| HPV (40)* | 0.11 | 148 | 755 | Dominated |
| HPV (40)* + Rx | 0.34 | 668 | 502 | Dominated |
| HPVAC(12), \$0.60/vaccine dose | 0.07 | 207 | 337 | Dominated |
| HPVAC (12), \$0.60/vaccine dose + Rx | 0.31 | 599 | 510 | Dominated |
| HPVAC (12), \$2.00/vaccine dose | 0.14 | 207 | 675 | Dominated |
| HPVAC (12), \$2.00/vaccine dose + Rx | 0.38 | 599 | 635 | Dominated |
| Pap(1,20,65)*+HPVAC (12,\$.60) | 1.00 | 415 | 2,417 | Dominated |
| Pap(3,20,65)*+HPVAC (12,\$.60) | 0.63 | 390 | 1,621 | Dominated |
| VIA(40)*+HPVAC (12), \$.60) | 0.11 | 265 | 422 | Dominated |
| Pap(1,20,65)*+HPVAC (12, \$.60) + Rx | 1.16 | 774 | 1,498 | Dominated |
| Pap(3,20,65)*+HPVAC (12, \$.60) + Rx | 0.79 | 754 | 1,053 | Dominated |
| VIA(40)*+HPVAC (12, \$.60) + Rx | 0.32 | 646 | 498 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) | 0.44 | 374 | 1,178 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) + Rx | 0.61 | 739 | 829 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60) | 2.15 | 426 | 5,057 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60)+Rx | 2.30 | 785 | 2,935 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60) | 1.06 | 407 | 2,618 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60)+Rx | 1.22 | 769 | 1,585 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60) | 0.70 | 396 | 1,778 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60)+Rx | 0.86 | 759 | 1,138 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60) | 0.16 | 302 | 527 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.38 | 676 | 561 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60) | 0.34 | 312 | 1,100 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.54 | 684 | 790 | Dominated |

| | | | | |
|---|------|-------|-------|-----------|
| VIA (35,40,45)* +HPVAC (12,\$.60) | 0.35 | 309 | 1,123 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.38 | 682 | 564 | Dominated |
| Pap (40)* +HPVAC (12,\$.60) | 0.10 | 258 | 398 | Dominated |
| Pap (40)* +HPVAC (12,\$.60)+Rx | 0.31 | 640 | 490 | Dominated |
| HPV (40)* +HPVAC (12,\$.60) | 0.17 | 267 | 634 | Dominated |
| HPV (40)* +HPVAC (12,\$.60)+Rx | 0.38 | 648 | 585 | Dominated |
| 95% coverage | | | | |
| Pap (1,20,65)* | 1.32 | 376 | 3,502 | Dominated |
| Pap (3,20,65)* | 0.70 | 324 | 2,166 | Dominated |
| VIA (40)* | 0.06 | 168 | 369 | Dominated |
| Rx | 0.25 | 626 | 401 | 702 |
| Pap (1,20,65)* + Rx | 1.54 | 917 | 1,681 | Dominated |
| Pap (3,20,65)* + Rx | 0.94 | 879 | 1,069 | Dominated |
| VIA (40)* + Rx | 0.37 | 784 | 475 | Dominated |
| Pap (5,20,65)* | 0.46 | 296 | 1,552 | Dominated |
| Pap (5,20,65)* + Rx | 0.71 | 856 | 830 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) | 2.68 | 395 | 6,802 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) + Rx | 2.75 | 935 | 2,941 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) | 1.15 | 351 | 3,283 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) + Rx | 1.28 | 901 | 1,421 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) | 0.73 | 333 | 2,206 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) + Rx | 0.97 | 886 | 1,091 | Dominated |
| Pap (35,40,45)*. | 0.12 | 239 | 484 | Dominated |
| Pap (35,40,45)* + Rx. | 0.44 | 836 | 522 | Dominated |
| HPV (35,40,45)*. | 0.33 | 265 | 1,239 | Dominated |
| HPV (35,40,45)* + Rx | 0.62 | 849 | 728 | Dominated |
| VIA (35,40,45) | 0.13 | 258 | 524 | Dominated |
| VIA (35,40,45)* + Rx | 0.43 | 844 | 505 | Dominated |
| Pap (40)* | 0.05 | 149 | 328 | Dominated |
| Pap (40)* + Rx | 0.36 | 770 | 471 | Dominated |
| HPV (40)* | 0.13 | 176 | 732 | Dominated |
| HPV (40)* + Rx | 0.44 | 790 | 552 | Dominated |
| HPVAC(12), \$0.60/vaccine dose | 0.08 | 245 | 333 | Dominated |
| HPVAC (12), \$0.60/vaccine dose + Rx | 0.43 | 813 | 523 | Dominated |
| HPVAC (12), \$2.00/vaccine dose | 0.16 | 245 | 670 | Dominated |
| HPVAC (12), \$2.00/vaccine dose + Rx | 0.51 | 813 | 633 | Dominated |
| Pap(1,20,65)*+HPVAC (12,\$.60) | 1.24 | 493 | 2,510 | Dominated |
| Pap(3,20,65)*+HPVAC (12,\$.60) | 0.72 | 464 | 1,553 | Dominated |
| VIA(40)*+HPVAC (12), \$.60) | 0.13 | 314 | 404 | Dominated |
| Pap(1,20,65)*+HPVAC (12, \$.60) + Rx | 1.46 | 1,003 | 1,456 | 27,139 |
| Pap(3,20,65)*+HPVAC (12, \$.60) + Rx | 0.95 | 982 | 970 | 12,425 |
| VIA(40)*+HPVAC (12, \$.60) + Rx | 0.43 | 862 | 500 | 972 |
| Pap(5,20,65)*+HPVAC (12, \$.60) | 0.50 | 444 | 1,122 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) + Rx | 0.75 | 965 | 772 | 3,906 |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60) | 2.60 | 506 | 5,147 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60)+Rx | 2.82 | 1,017 | 2,773 | 100,075 |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60) | 1.22 | 483 | 2,534 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60)+Rx | 1.44 | 999 | 1,447 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60) | 0.81 | 470 | 1,712 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60)+Rx | 1.03 | 988 | 1,048 | 13,705 |
| Pap (35,40,45)* +HPVAC (12,\$.60) | 0.19 | 358 | 521 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.50 | 895 | 564 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60) | 0.40 | 370 | 1,078 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.69 | 904 | 758 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60) | 0.40 | 367 | 1,099 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.50 | 901 | 550 | 1,675 |

| | | | | |
|--------------------------------|------|-----|-----|-----------|
| Pap (40)* +HPVAC (12,\$.60) | 0.12 | 306 | 391 | Dominated |
| Pap (40)* +HPVAC (12,\$.60)+Rx | 0.43 | 857 | 497 | 756 |
| HPV (40)* +HPVAC (12,\$.60) | 0.20 | 318 | 621 | Dominated |
| HPV (40)* +HPVAC (12,\$.60)+Rx | 0.50 | 865 | 579 | Dominated |

World sub-region Sear-D

| | | | | |
|---|------|-------|-------|-----------|
| Current Scenario | 0.08 | 207 | 372 | Dominated |
| 50% coverage | | | | |
| Pap (1,20,65)* | 0.49 | 145 | 3,359 | Dominated |
| Pap (3,20,65)* | 0.39 | 125 | 3,088 | Dominated |
| VIA (40)* | 0.05 | 65 | 727 | Dominated |
| Rx | 0.07 | 390 | 184 | Dominated |
| Pap (1,20,65)* + Rx | 0.55 | 646 | 855 | Dominated |
| Pap (3,20,65)* + Rx | 0.46 | 629 | 737 | Dominated |
| VIA (40)* + Rx | 0.21 | 1,333 | 154 | Dominated |
| Pap (5,20,65)* | 0.26 | 116 | 2,235 | Dominated |
| Pap (5,20,65)* + Rx | 0.35 | 618 | 558 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) | 1.33 | 151 | 8,787 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) + Rx | 1.37 | 654 | 2,100 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) | 0.70 | 134 | 5,254 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) + Rx | 0.76 | 638 | 1,196 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) | 0.46 | 127 | 3,578 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) + Rx | 0.54 | 630 | 850 | Dominated |
| Pap (35,40,45)*. | 0.07 | 89 | 746 | Dominated |
| Pap (35,40,45)* + Rx. | 0.24 | 1,361 | 174 | Dominated |
| HPV (35,40,45)*. | 0.22 | 98 | 2,256 | Dominated |
| HPV (35,40,45)* + Rx | 0.37 | 1,274 | 290 | Dominated |
| VIA (35,40,45) | 0.11 | 96 | 1,150 | Dominated |
| VIA (35,40,45)* + Rx | 0.26 | 1,272 | 204 | Dominated |
| Pap (40)* | 0.03 | 58 | 487 | Dominated |
| Pap (40)* + Rx | 0.19 | 1,327 | 142 | 142 |
| HPV (40)* | 0.09 | 69 | 1,278 | Dominated |
| HPV (40)* + Rx | 0.25 | 1,336 | 184 | Dominated |
| HPVAC(12), \$0.60/vaccine dose | 0.03 | 114 | 298 | Dominated |
| HPVAC (12), \$0.60/vaccine dose + Rx | 0.15 | 496 | 305 | Dominated |
| HPVAC (12), \$2.00/vaccine dose | 0.07 | 114 | 605 | Dominated |
| HPVAC (12), \$2.00/vaccine dose + Rx | 0.19 | 496 | 382 | Dominated |
| Pap(1,20,65)*+HPVAC (12,\$.60) | 0.48 | 203 | 2,380 | Dominated |
| Pap(3,20,65)*+HPVAC (12,\$.60) | 0.40 | 193 | 2,081 | Dominated |
| VIA(40)*+HPVAC (12), \$.60) | 0.07 | 141 | 518 | Dominated |
| Pap(1,20,65)*+HPVAC (12, \$.60) + Rx | 0.56 | 583 | 953 | Dominated |
| Pap(3,20,65)*+HPVAC (12, \$.60) + Rx | 0.48 | 574 | 832 | Dominated |
| VIA(40)*+HPVAC (12, \$.60) + Rx | 0.18 | 521 | 338 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) | 0.28 | 187 | 1,505 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) + Rx | 0.36 | 567 | 642 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60) | 1.33 | 207 | 6,424 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60)+Rx | 1.40 | 589 | 2,378 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60) | 0.73 | 199 | 3,673 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60)+Rx | 0.80 | 581 | 1,384 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60) | 0.48 | 195 | 2,482 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60)+Rx | 0.56 | 576 | 974 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60) | 0.10 | 156 | 613 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.21 | 535 | 384 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60) | 0.25 | 160 | 1,567 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.35 | 539 | 646 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60) | 0.26 | 159 | 1,609 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.24 | 538 | 443 | Dominated |

| | | | | |
|---|------|-------|-------|-----------|
| Pap (40)* +HPVAC (12,\$.60) | 0.06 | 138 | 414 | Dominated |
| Pap (40)* +HPVAC (12,\$.60)+Rx | 0.16 | 518 | 310 | Dominated |
| HPV (40)* +HPVAC (12,\$.60) | 0.11 | 142 | 810 | Dominated |
| HPV (40)* +HPVAC (12,\$.60)+Rx | 0.22 | 522 | 418 | Dominated |
| 80% coverage | | | | |
| Pap (1,20,65)* | 0.76 | 233 | 3,281 | Dominated |
| Pap (3,20,65)* | 0.48 | 201 | 2,391 | Dominated |
| VIA (40)* | 0.05 | 105 | 506 | Dominated |
| Rx | 0.18 | 965 | 183 | Dominated |
| Pap (1,20,65)* + Rx | 0.94 | 1,248 | 753 | Dominated |
| Pap (3,20,65)* + Rx | 0.67 | 1,225 | 549 | Dominated |
| VIA (40)* + Rx | 0.36 | 1,573 | 229 | Dominated |
| Pap (5,20,65)* | 0.32 | 185 | 1,716 | Dominated |
| Pap (5,20,65)* + Rx | 0.53 | 1,208 | 436 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) | 2.12 | 242 | 8,770 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) + Rx | 2.22 | 1,266 | 1,756 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) | 0.95 | 214 | 4,455 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) + Rx | 1.10 | 1,240 | 891 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) | 0.61 | 204 | 2,978 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) + Rx | 0.80 | 1,227 | 651 | Dominated |
| Pap (35,40,45)*. | 0.09 | 143 | 628 | Dominated |
| Pap (35,40,45)* + Rx. | 0.42 | 1,608 | 259 | Dominated |
| HPV (35,40,45) *. | 0.32 | 157 | 2,009 | Dominated |
| HPV (35,40,45) * + Rx | 0.61 | 1,568 | 386 | Dominated |
| VIA (35,40,45) | 0.12 | 153 | 797 | Dominated |
| VIA (35,40,45) * + Rx | 0.41 | 1,565 | 264 | Dominated |
| Pap (40) * | 0.04 | 93 | 400 | Dominated |
| Pap (40) * + Rx | 0.35 | 1,564 | 222 | Dominated |
| HPV (40) * | 0.12 | 110 | 1,125 | Dominated |
| HPV (40) * + Rx | 0.43 | 1,577 | 272 | Dominated |
| HPVAC(12), \$0.60/vaccine dose | 0.05 | 183 | 287 | Dominated |
| HPVAC (12), \$0.60/vaccine dose + Rx | 0.35 | 1,122 | 309 | Dominated |
| HPVAC (12), \$2.00/vaccine dose | 0.11 | 183 | 594 | Dominated |
| HPVAC (12), \$2.00/vaccine dose + Rx | 0.41 | 1,122 | 363 | Dominated |
| Pap(1,20,65)*+HPVAC (12,\$.60) | 0.74 | 326 | 2,283 | Dominated |
| Pap(3,20,65)*+HPVAC (12,\$.60) | 0.50 | 310 | 1,618 | Dominated |
| VIA(40)*+HPVAC (12), \$.60) | 0.09 | 225 | 417 | Dominated |
| Pap(1,20,65)*+HPVAC (12, \$.60) + Rx | 0.92 | 1,253 | 731 | Dominated |
| Pap(3,20,65)*+HPVAC (12, \$.60) + Rx | 0.69 | 1,242 | 553 | Dominated |
| VIA(40)*+HPVAC (12, \$.60) + Rx | 0.35 | 1,157 | 302 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) | 0.35 | 299 | 1,161 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) + Rx | 0.55 | 1,230 | 448 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60) | 2.10 | 332 | 6,326 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60)+Rx | 2.26 | 1,267 | 1,787 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60) | 1.00 | 319 | 3,133 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60)+Rx | 1.17 | 1,254 | 936 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60) | 0.65 | 312 | 2,088 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60)+Rx | 0.84 | 1,245 | 674 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60) | 0.13 | 249 | 542 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.41 | 1,178 | 345 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60) | 0.36 | 255 | 1,412 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.60 | 1,184 | 510 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60) | 0.37 | 254 | 1,441 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.41 | 1,182 | 349 | Dominated |
| Pap (40)* +HPVAC (12,\$.60) | 0.08 | 220 | 373 | Dominated |
| Pap (40)* +HPVAC (12,\$.60)+Rx | 0.34 | 1,153 | 293 | Dominated |

| | | | | |
|---|------|-------|-------|-----------|
| HPV (40)* +HPVAC (12,\$.60) | 0.17 | 227 | 736 | Dominated |
| HPV (40)* +HPVAC (12,\$.60)+Rx | 0.42 | 1,158 | 364 | Dominated |
| 95% coverage | | | | |
| Pap (1,20,65)* | 0.95 | 276 | 3,424 | Dominated |
| Pap (3,20,65)* | | | | |
| VIA (40)* | 0.06 | 124 | 458 | Dominated |
| Rx | 0.27 | 1,507 | 182 | |
| Pap (1,20,65)* + Rx | 1.22 | 1,766 | 688 | |
| Pap (3,20,65)* + Rx | 0.84 | 1,744 | 480 | Dominated |
| VIA (40)* + Rx | 0.48 | 1,765 | 269 | 1,240 |
| Pap (5,20,65)* | 0.36 | 220 | 1,617 | Dominated |
| Pap (5,20,65)* + Rx | 0.68 | 1,722 | 392 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) | 2.56 | 287 | 8,907 | Dominated |
| Pap (1,20,30) then Pap & HPV (1,30,65) + Rx | 2.72 | 1,793 | 1,515 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) | 1.09 | 255 | 4,283 | Dominated |
| Pap (3,20,30) then Pap & HPV (3,30,65) + Rx | 1.32 | 1,763 | 748 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) | 0.69 | 242 | 2,845 | Dominated |
| Pap (5,20,30) then Pap & HPV (5,30,65) + Rx | 0.98 | 1,746 | 564 | Dominated |
| Pap (35,40,45)*. | 0.10 | 170 | 608 | Dominated |
| Pap (35,40,45)* + Rx. | 0.55 | 1,803 | 303 | 2,886 |
| HPV (35,40,45)*. | 0.36 | 187 | 1,954 | Dominated |
| HPV (35,40,45)* + Rx | 0.76 | 1,800 | 423 | Dominated |
| VIA (35,40,45) | 0.13 | 182 | 714 | Dominated |
| VIA (35,40,45)* + Rx | 0.53 | 1,796 | 294 | 1,719 |
| Pap (40)* | 0.04 | 111 | 384 | Dominated |
| Pap (40)* + Rx | 0.46 | 1,755 | 264 | 757 |
| HPV (40)* | 0.14 | 130 | 1,091 | Dominated |
| HPV (40)* + Rx | 0.56 | 1,770 | 315 | Dominated |
| HPVAC(12), \$0.60/vaccine dose | 0.06 | 217 | 284 | Dominated |
| HPVAC (12), \$0.60/vaccine dose + Rx | 0.52 | 1,679 | 311 | Dominated |
| HPVAC (12), \$2.00/vaccine dose | 0.13 | 217 | 591 | Dominated |
| HPVAC (12), \$2.00/vaccine dose + Rx | 0.60 | 1,679 | 355 | Dominated |
| Pap(1,20,65)*+HPVAC (12,\$.60) | 0.90 | 387 | 2,329 | Dominated |
| Pap(3,20,65)*+HPVAC (12,\$.60) | 0.56 | 368 | 1,522 | Dominated |
| VIA(40)*+HPVAC (12), \$.60) | 0.11 | 267 | 393 | Dominated |
| Pap(1,20,65)*+HPVAC (12, \$.60) + Rx | 1.17 | 1,830 | 639 | Dominated |
| Pap(3,20,65)*+HPVAC (12, \$.60) + Rx | 0.85 | 1,822 | 467 | 16,051 |
| VIA(40)*+HPVAC (12, \$.60) + Rx | 0.50 | 1,717 | 293 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) | 0.39 | 355 | 1,088 | Dominated |
| Pap(5,20,65)*+HPVAC (12, \$.60) + Rx | 0.70 | 1,805 | 389 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60) | 2.51 | 394 | 6,371 | Dominated |
| Pap (1,20,30) & Pap/HPV(1,30,65)*+HPVAC (12,\$.60)+Rx | 2.77 | 1,854 | 1,493 | 81,629 |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60) | 1.14 | 379 | 3,018 | Dominated |
| Pap (3,20,30) & Pap/HPV(3,30,65)*+HPVAC (12,\$.60)+Rx | 1.41 | 1,837 | 770 | 36,764 |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60) | 0.74 | 371 | 2,001 | Dominated |
| Pap (5,20,30) & Pap/HPV(5,30,65)*+HPVAC (12,\$.60)+Rx | 1.03 | 1,824 | 567 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60) | 0.16 | 296 | 529 | Dominated |
| Pap (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.58 | 1,741 | 333 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60) | 0.42 | 303 | 1,377 | Dominated |
| HPV (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.80 | 1,747 | 456 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60) | 0.42 | 301 | 1,403 | Dominated |
| VIA (35,40,45)* +HPVAC (12,\$.60)+Rx | 0.57 | 1,745 | 324 | Dominated |
| Pap (40)* +HPVAC (12,\$.60) | 0.10 | 262 | 365 | Dominated |
| Pap (40)* +HPVAC (12,\$.60)+Rx | 0.49 | 1,712 | 289 | Dominated |
| HPV (40)* +HPVAC (12,\$.60) | 0.19 | 270 | 719 | Dominated |
| HPV (40)* +HPVAC (12,\$.60)+Rx | 0.59 | 1,718 | 344 | Dominated |

Notes:-

Rx: Treatment of invasive cancer including chemotherapy and/or radiotherapy and/or surgery.

* Including removal of lesions.

(f,Y,z) Screening every f years from age y to age z.

HPVAC (12): Vaccinations against HPV starting at age 12.

(40) Intervention at age 40

(35,40,45) Intervention at ages 35,40 and 45.

Appendix 5

Annual costs, effects and cost-effectiveness of interventions in colorectal cancer control
(cost and effects discounted and effects age-weighted)

| Intervention | Costs per capita (I\$) | DALYS averted (per mln people) | Cost per DALY | |
|-------------------------------|------------------------|--------------------------------|---------------|-----------|
| | | | ACER | ICER |
| World sub-region Afr-E | | | | |
| Current Scenario | 0.04 | 32 | 1,217 | Dominated |
| 50% coverage | | | | |
| FOB1* | 0.51 | 86 | 5,920 | Dominated |
| FOB2* | 0.28 | 58 | 4,797 | Dominated |
| SIG5* | 0.33 | 78 | 4,265 | Dominated |
| COL10* | 0.30 | 109 | 2,807 | Dominated |
| SIG5* & FOB1* | 0.67 | 105 | 6,367 | Dominated |
| FOB(50)* | 0.05 | 10 | 5,159 | Dominated |
| SIG(50)* | 0.09 | 36 | 2,576 | Dominated |
| COL(50)* | 0.18 | 78 | 2,299 | Dominated |
| SIG(50)* & FOB(50) * | 0.12 | 40 | 2,969 | Dominated |
| Rx | 0.14 | 363 | 382 | Dominated |
| FOB1* + Rx | 0.63 | 459 | 1,381 | Dominated |
| FOB2* + Rx | 0.41 | 431 | 946 | Dominated |
| SIG5* + Rx | 0.40 | 437 | 919 | Dominated |
| COL10* + Rx | 0.44 | 461 | 945 | Dominated |
| SIG5* & FOB1* + Rx | 0.55 | 467 | 1,172 | Dominated |
| FOB(50)*+ Rx | 0.19 | 383 | 495 | Dominated |
| SIG(50) + Rx | 0.23 | 402 | 565 | Dominated |
| COL (50)*+ Rx | 0.31 | 438 | 712 | Dominated |
| SIG(50)* & FOB(50)*+ Rx | 0.26 | 406 | 631 | Dominated |
| DRE1* | 0.10 | 8 | 11,787 | Dominated |
| DRE1* + Rx | 0.24 | 377 | 629 | Dominated |
| Fruit & Veg campaign | 0.04 | 3 | 14,985 | Dominated |
| Fruit & Veg campaign + Rx | 0.18 | 274 | 641 | Dominated |
| 80% coverage | | | | |
| FOB1* | 0.82 | 137 | 5,977 | Dominated |
| FOB2* | 0.45 | 93 | 4,816 | Dominated |
| SIG5* | 0.53 | 125 | 4,219 | Dominated |
| COL10* | 0.48 | 174 | 2,770 | Dominated |
| SIG5* & FOB1* | 1.08 | 168 | 6,405 | Dominated |
| FOB(50)* | 0.08 | 17 | 4,891 | Dominated |
| SIG(50)* | 0.14 | 57 | 2,467 | Dominated |
| COL(50)* | 0.28 | 125 | 2,250 | Dominated |
| SIG(50)* & FOB(50) * | 0.18 | 64 | 2,898 | Dominated |
| Rx | 0.27 | 819 | 336 | 336 |
| FOB1* + Rx | 1.07 | 942 | 1,132 | Dominated |
| FOB2* + Rx | 0.70 | 907 | 775 | Dominated |
| SIG5* + Rx | 0.68 | 908 | 754 | Dominated |

| | | | | |
|---------------------------|------|-------|--------|-----------|
| COL10* + Rx | 0.74 | 936 | 787 | Dominated |
| SIG5* & FOBT1* + Rx | 0.93 | 950 | 976 | Dominated |
| FOB(50)*+ Rx | 0.35 | 842 | 419 | Dominated |
| SIG(50) + Rx | 0.41 | 865 | 474 | Dominated |
| COL (50)*+ Rx | 0.54 | 911 | 598 | Dominated |
| SIG(50)* & FOB(50)*+ Rx | 0.46 | 872 | 527 | Dominated |
| DRE1* | 0.15 | 13 | 11,305 | Dominated |
| DRE1* + Rx | 0.43 | 833 | 516 | Dominated |
| Fruit & Veg campaign | 0.06 | 8 | 8,375 | Dominated |
| Fruit & Veg campaign + Rx | 0.33 | 708 | 463 | Dominated |
| 95% coverage | | | | |
| FOB1* | 0.98 | 154 | 6,358 | Dominated |
| FOB2* | 0.53 | 104 | 5,114 | Dominated |
| SIG5* | 0.63 | 141 | 4,443 | Dominated |
| COL10* | 0.57 | 196 | 2,915 | Dominated |
| SIG5* & FOB1* | 1.29 | 190 | 6,797 | Dominated |
| FOB(50)* | 0.10 | 19 | 5,121 | Dominated |
| SIG(50)* | 0.17 | 64 | 2,576 | Dominated |
| COL(50)* | 0.33 | 140 | 2,362 | Dominated |
| SIG(50)* & FOB(50) * | 0.22 | 72 | 3,047 | Dominated |
| Rx | 0.36 | 1,066 | 336 | 337 |
| FOB1* + Rx | 1.30 | 1,185 | 1,098 | Dominated |
| FOB2* + Rx | 0.87 | 1,151 | 752 | Dominated |
| SIG5* + Rx | 0.84 | 1,150 | 731 | Dominated |
| COL10* + Rx | 0.90 | 1,177 | 766 | 9,598 |
| SIG5* & FOBT1* + Rx | 1.13 | 1,192 | 952 | 15,548 |
| FOB(50)*+ Rx | 0.45 | 1,088 | 413 | Dominated |
| SIG(50) + Rx | 0.52 | 1,109 | 465 | Dominated |
| COL (50)*+ Rx | 0.67 | 1,153 | 585 | 3,630 |
| SIG(50)* & FOB(50)*+ Rx | 0.58 | 1,116 | 516 | Dominated |
| DRE1* | 0.18 | 15 | 11,841 | Dominated |
| DRE1* + Rx | 0.54 | 1,079 | 503 | Dominated |
| Fruit & Veg campaign | 0.08 | 10 | 8,579 | Dominated |
| Fruit & Veg campaign + Rx | 0.43 | 979 | 443 | Dominated |

World sub-region Sear-D

| | | | | |
|-------------------------|------|----|--------|-----------|
| Current Scenario | 0.05 | 69 | 694 | Dominated |
| 50% coverage | | | | |
| FOB1* | 0.70 | 53 | 13,069 | Dominated |
| FOB2* | 0.38 | 36 | 10,476 | Dominated |
| SIG5* | 0.42 | 49 | 8,685 | Dominated |
| COL10* | 0.39 | 65 | 5,982 | Dominated |
| SIG5* & FOB1* | 0.90 | 65 | 13,857 | Dominated |

| | | | | |
|---------------------------|------|-----|--------|-----------|
| FOB(50)* | 0.07 | 6 | 10,701 | Dominated |
| SIG(50)* | 0.11 | 22 | 5,002 | Dominated |
| COL(50)* | 0.23 | 47 | 4,806 | Dominated |
| SIG(50)* & FOB(50) * | 0.15 | 24 | 6,245 | Dominated |
| Rx | 0.12 | 274 | 425 | Dominated |
| FOB1* + Rx | 0.80 | 336 | 2,396 | Dominated |
| FOB2* + Rx | 0.49 | 319 | 1,534 | Dominated |
| SIG5* + Rx | 0.45 | 321 | 1,407 | Dominated |
| COL10* + Rx | 0.50 | 333 | 1,505 | Dominated |
| SIG5* & FOBT1* + Rx | 0.69 | 341 | 2,012 | Dominated |
| FOB(50)*+ Rx | 0.18 | 288 | 633 | Dominated |
| SIG(50) + Rx | 0.22 | 299 | 744 | Dominated |
| COL (50)*+ Rx | 0.34 | 321 | 1,052 | Dominated |
| SIG(50)* & FOB(50)*+ Rx | 0.28 | 302 | 931 | Dominated |
| DRE1* | 0.10 | 5 | 19,935 | Dominated |
| DRE1* + Rx | 0.26 | 284 | 901 | Dominated |
| Fruit & Veg campaign | 0.02 | 1 | 14,818 | Dominated |
| Fruit & Veg campaign + Rx | 0.13 | 194 | 653 | Dominated |

80% coverage

| | | | | |
|---------------------------|------|-----|--------|-----------|
| FOB1* | 1.26 | 86 | 14,696 | Dominated |
| FOB2* | 0.67 | 58 | 11,685 | Dominated |
| SIG5* | 0.68 | 78 | 8,770 | Dominated |
| COL10* | 0.63 | 104 | 5,998 | Dominated |
| SIG5* & FOB1* | 1.59 | 104 | 15,182 | Dominated |
| FOB(50)* | 0.12 | 10 | 11,938 | Dominated |
| SIG(50)* | 0.17 | 35 | 4,944 | Dominated |
| COL(50)* | 0.36 | 75 | 4,792 | Dominated |
| SIG(50)* & FOB(50) * | 0.25 | 39 | 6,566 | Dominated |
| Rx | 0.23 | 598 | 387 | Dominated |
| FOB1* + Rx | 1.47 | 676 | 2,171 | Dominated |
| FOB2* + Rx | 0.89 | 654 | 1,368 | Dominated |
| SIG5* + Rx | 0.77 | 653 | 1,182 | Dominated |
| COL10* + Rx | 0.85 | 666 | 1,269 | Dominated |
| SIG5* & FOBT1* + Rx | 1.27 | 679 | 1,876 | Dominated |
| FOB(50)*+ Rx | 0.35 | 613 | 571 | Dominated |
| SIG(50) + Rx | 0.40 | 626 | 638 | Dominated |
| COL (50)*+ Rx | 0.58 | 652 | 891 | Dominated |
| SIG(50)* & FOB(50)*+ Rx | 0.52 | 630 | 828 | Dominated |
| DRE1* | 0.17 | 8 | 21,306 | Dominated |
| DRE1* + Rx | 0.50 | 608 | 828 | Dominated |
| Fruit & Veg campaign | 0.02 | 3 | 7,586 | Dominated |
| Fruit & Veg campaign + Rx | 0.24 | 505 | 483 | Dominated |

95% coverage

| | | | | |
|------------------|------|----|-----|-----------|
| Current Scenario | 0.05 | 69 | 694 | Dominated |
|------------------|------|----|-----|-----------|

| | | | | |
|--------------------------|------|-----|--------|-----------|
| FOB1* | 1.58 | 102 | 15,525 | Dominated |
| FOB2* | 0.84 | 69 | 12,304 | Dominated |
| SIG5* | 0.81 | 92 | 8,824 | Dominated |
| COL10* | 0.74 | 124 | 6,014 | Dominated |
| SIG5* & FOB1* | 1.97 | 124 | 15,859 | Dominated |
| FOB(50)* | 0.15 | 12 | 12,633 | Dominated |
| SIG(50)* | 0.20 | 41 | 4,938 | Dominated |
| COL(50)* | 0.43 | 89 | 4,795 | Dominated |
| SIG(50)* & FOB(50)* | 0.31 | 46 | 6,747 | Dominated |
| Rx | 0.31 | 868 | 362 | 362 |
| FOB1* + Rx | 1.86 | 936 | 1,985 | Dominated |
| FOB2* + Rx | 1.14 | 917 | 1,242 | Dominated |
| SIG5* + Rx | 0.96 | 915 | 1,046 | Dominated |
| COL10* + Rx | 1.04 | 926 | 1,124 | 28,017 |
| SIG5* & FOB1* + Rx | 1.63 | 939 | 1,735 | 42,940 |
| FOB(50)* + Rx | 0.46 | 880 | 525 | Dominated |
| SIG(50) + Rx | 0.51 | 891 | 574 | 8,291 |
| COL (50)* + Rx | 0.73 | 914 | 794 | 9,318 |
| SIG(50)* & FOB(50)* + Rx | 0.67 | 895 | 753 | Dominated |
| DRE1* | 0.22 | 10 | 22,133 | Dominated |
| DRE1* + Rx | 0.67 | 875 | 761 | Dominated |
| Fruit & Veg campaign | 0.03 | 5 | 6,903 | Dominated |

Notes:

* Includes surgical removal of polyps.

Rx: Treatment of invasive cancer including chemotherapy and/or radiotherapy and/or surgery.

ZZZY denotes screening with intervention ZZZ every Y years

(x) denotes screening at age "x"

FOB: Fecal Occult Blood Test

SIG: Sigmoidoscopy

COL: Colonoscopy

DRE : Digital Rectal Examination

Appendix 6

Annual costs, effects and cost-effectiveness of interventions in breast cancer control (cost and effects discounted and effects age-weighted)

| Intervention | Costs per capita (I\$) | DALYS averted (per mln people) | Cost per DALY | |
|--------------------------------|------------------------|--------------------------------|---------------|-----------|
| | | | ACER | ICER |
| World sub-region Afr-E | | | | |
| Stage I treatment 50% | 0,11 | 28 | 3.800 | Dominated |
| Stage II treatment 50% | 0,12 | 15 | 7.855 | Dominated |
| Stage III treatment 50% | 0,22 | 44 | 5.042 | Dominated |
| Stage IV treatment 50% | 0,11 | 2 | 51.767 | Dominated |
| Treatment all stages 50% | 0,32 | 87 | 3.705 | Dominated |
| Optimal program 50% | 0,68 | 303 | 2.248 | 2.248 |
| Stage I treatment 80% | 0,17 | 45 | 3.686 | Dominated |
| Stage II treatment 80% | 0,18 | 24 | 7.640 | Dominated |
| Stage III treatment 80% | 0,35 | 70 | 4.974 | Dominated |
| Stage IV treatment 80% | 0,17 | 3 | 50.221 | Dominated |
| Treatment all stages 80% | 0,51 | 140 | 3.661 | Dominated |
| Optimal program 80% | 1,09 | 485 | 2.253 | 2.261 |
| Stage I treatment 95% | 0,19 | 54 | 3.610 | Dominated |
| Stage II treatment 95% | 0,21 | 28 | 7.496 | Dominated |
| Stage III treatment 95% | 0,41 | 84 | 4.929 | Dominated |
| Stage IV treatment 95% | 0,20 | 4 | 49.218 | Dominated |
| Treatment all stages 95% | 0,61 | 166 | 3.690 | Dominated |
| Optimal program 95% | 1,34 | 576 | 2.323 | 2.696 |
| World sub-region Sear-D | | | | |
| Stage I treatment 50% | 0,08 | 19 | 4.548 | Dominated |
| Stage II treatment 50% | 0,11 | 11 | 9.802 | Dominated |
| Stage III treatment 50% | 0,18 | 35 | 5.032 | Dominated |
| Stage IV treatment 50% | 0,09 | 2 | 49.891 | Dominated |
| Treatment all stages 50% | 0,30 | 65 | 4.569 | Dominated |
| Optimal program 50% | 0,87 | 201 | 4.338 | 4.338 |
| Stage I treatment 80% | 0,13 | 30 | 4.479 | Dominated |
| Stage II treatment 80% | 0,17 | 18 | 9.717 | Dominated |
| Stage III treatment 80% | 0,28 | 57 | 4.997 | Dominated |
| Stage IV treatment 80% | 0,14 | 3 | 49.169 | Dominated |
| Treatment all stages 80% | 0,47 | 105 | 4.534 | Dominated |
| Optimal program 80% | 1,40 | 321 | 4.362 | 4.401 |
| Stage I treatment 95% | 0,15 | 35 | 4.362 | Dominated |
| Stage II treatment 95% | 0,20 | 21 | 9.494 | Dominated |
| Stage III treatment 95% | 0,33 | 67 | 4.937 | Dominated |

| | | | | |
|--------------------------|------|-----|--------|-----------|
| Stage IV treatment 95% | 0,16 | 3 | 47.947 | Dominated |
| Treatment all stages 95% | 0,56 | 124 | 4.533 | Dominated |
| Optimal program 95% | 1,68 | 381 | 4.399 | 4.596 |
